Genzyme Corp.’s interim results from a Phase II trial comparing Campath with Rebif for the treatment of multiple sclerosis show efficacy. The results are from a pre-specified analysis conducted after two years of treatment for 334 patients in the three-year trial. As previously disclosed, dosing of Campath was suspended in September 2005 after three patients developed immune thrombocytopenic purpura (ITP), a condition causing a low platelet count as a result of an immune response di...